Welcome to our dedicated page for PHOENIX RISING COS news (Ticker: PRCX), a resource for investors and traders seeking the latest updates and insights on PHOENIX RISING COS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PHOENIX RISING COS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PHOENIX RISING COS's position in the market.
Phoenix Rising Companies (PRCX) announced progress in its planned acquisition of Morpheus Robotics, Inc., headquartered in Italy. CEO DS Chang highlighted the advancements in Morpheus' product development, particularly in robotic devices for dental implantation. These innovations aim to enhance surgical accuracy and reduce both complications and costs. The parties are finalizing the Share Exchange Agreement, with completion expected soon. The acquisition is anticipated to significantly grow Phoenix's market presence and benefits for stakeholders.
Phoenix Rising Companies has announced a Memorandum of Understanding (MOU) to acquire all outstanding shares of Morpheus Robotics, a Singapore-based company specializing in advanced medical technologies, including AI-driven robotics and imaging systems. The transaction involves issuing 100 million restricted shares and obtaining $8 million for financing. This acquisition aims to enhance Phoenix's growth potential and market presence in the medical sector. The deal is contingent upon various conditions, including board approvals and final contract negotiations.
Phoenix Rising Companies (OTCQB:PRCX) has finalized a MOU to acquire Emvera Technologies, a distributor of aesthetic medical devices, including lasers and energy-based systems. Founded in 2012, Emvera operates in a rapidly expanding market projected to grow at a CAGR of 15.2% through 2030. The acquisition will involve the issuance of approximately 46 million common restricted shares and aims to enhance Phoenix's market position. Emvera's sales are rebounding post-pandemic, bolstered by pending strategic alliances. Further details on the formal acquisition agreement are expected within 90 days.
PARK CITY, UT / ACCESSWIRE / January 31, 2022 / Phoenix Rising Companies (OTCQB:PRCX) is advancing its plans to expand its operations in sustainable energy and biotech. The company is negotiating for exclusive rights to two groundbreaking technologies, with details to be announced in February 2022. Additional technologies are also under consideration. CEO DS Chang emphasized potential economic benefits for shareholders, although additional testing is necessary. The company advises caution regarding forward-looking statements due to inherent risks.
Phoenix Rising Companies (OTCQB:PRCX) provided a year-end update expressing gratitude to stakeholders for their support during a challenging 2021.
The company's core subsidiary, Tieshan Oil, remains operational with an expected substantial revenue from gasoline refining despite pandemic disruptions.
However, the planned Wandi mining acquisition faced obstacles due to Covid-19 restrictions in China, leading to a shift in focus towards Western opportunities.
The Board aims to enhance shareholder value through innovative technologies and is in the early planning stages of establishing a new R&D division in the U.S.
Phoenix Rising Companies (OTCQB:PRCX) announced its decision to unwind the Wandi Mining acquisition due to regulatory conflicts with the Chinese government affecting foreign investment.
As management pivots towards U.S.-based acquisitions, they are finalizing a letter of intent with an aesthetic medical device company. The company aims to focus on investments with predictable regulatory environments, moving away from the uncertainties in China in light of recent government policies.
FAQ
What is the market cap of PHOENIX RISING COS (PRCX)?
